title: Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
abstract: BACKGROUND
  Data from an open label randomised controlled trial have suggested possible advantages on both motor and non-motor measures in patients with Parkinson's disease following 12 months exposure to exenatide.
  
  
  OBJECTIVE
  Continued follow up of these same patients was performed to investigate whether these possible advantages persisted in the prolonged absence of this medication.
  
  
  METHODS
  All participants from an open label, randomised controlled trial of exenatide as a treatment for Parkinson's disease, were invited for a further follow up assessment at the UCL Institute of Neurology. This visit included all 20 individuals who had previously completed twelve months exposure to exenatide 10ug bd and the 24 individuals who had acted as randomised controls. Motor severity of PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the MDS-UPDRS, together with several non-motor tests. This assessment was thus 24 months after their original baseline visit, i.e. 12 months after cessation of exenatide.
  
  
  RESULTS
  Compared to the control group of patients, patients previously exposed to exenatide had an advantage of 5.6 points (95% CI, 2.2-9.0; p = 0.002) using blinded video rating of the MDS-UPDRS part 3 motor subscale. There was also a difference of 5.3 points; (95% CI, 9.3-1.4; p = 0.006) between the 2 groups on the Mattis Dementia Rating scale.
  
  
  CONCLUSIONS
  While these data must still not be interpreted as evidence of neuroprotection, they nevertheless provide strong encouragement for the further study of this drug as a potential disease modifying agent in Parkinson's disease.
authors.affiliation: Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.
authors.forename: Iciar
authors.initials: I
authors.lastname: Aviles-Olmos
authors.affiliation: Department of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK.
authors.forename: John
authors.initials: J
authors.lastname: Dickson
authors.affiliation: Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.
authors.forename: Zinovia
authors.initials: Z
authors.lastname: Kefalopoulou
authors.affiliation: Reta Lila Weston Laboratories, London, UK.
authors.forename: Atbin
authors.initials: A
authors.lastname: Djamshidian
authors.affiliation: Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.
authors.forename: Joshua
authors.initials: J
authors.lastname: Kahan
authors.affiliation: Department of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Ell
authors.affiliation: UCL School of Pharmacy, London, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Whitton
authors.affiliation: The Cure Parkinson's Trust, St. Botolph's, London, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Wyse
authors.affiliation: The Cure Parkinson's Trust, St. Botolph's, London, UK.
authors.forename: Tom
authors.initials: T
authors.lastname: Isaacs
authors.affiliation: Reta Lila Weston Laboratories, London, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Lees
authors.affiliation: Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.
authors.forename: Patricia
authors.initials: P
authors.lastname: Limousin
authors.affiliation: Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.
authors.forename: Thomas
authors.initials: T
authors.lastname: Foltynie
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use*; D003071:Cognition; D000077270:Exenatide; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D000978:Antiparkinson Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide
keywords: Parkinson's disease; UPDRS; clinical trial; diabetes mellitus; disease modifying treatment; exenatide